Stoke Therapeutics’ Zorevunersen: A Promising First-in-Class Therapy for Dravet Syndrome with Strong Commercial Potential

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Buy rating on Stoke Therapeutics (STOK – Research Report). The associated price target was lowered to $35.00.

Andrew Fein has given his Buy rating due to a combination of factors related to Stoke Therapeutics’ promising drug, zorevunersen, for the treatment of Dravet syndrome. The drug has shown potential not only in significantly reducing seizure frequency but also in improving cognitive and behavioral outcomes, which current treatments do not address. This differentiation could position zorevunersen as a first-in-class therapy in a crowded market dominated by seizure reduction medications.
Fein notes that the ongoing Phase 3 EMPEROR trial, with its robust methodology and global regulatory alignment, is designed to validate these benefits, potentially leading to regulatory approval. The trial’s design, which includes a sham-controlled approach covering the U.S., EU, and Japan, reflects its credibility and could facilitate commercialization efforts. Additionally, the support from Biogen and the potential for payer acceptance based on real-world data further bolster the investment case, despite adjustments in price targets to align with current market conditions.

In another report released yesterday, Canaccord Genuity also reiterated a Buy rating on the stock with a $20.00 price target.